Evidence map›Paper›PMID 41083568›Full record

ArticleScientific reports2025

Risk stratification of acute exacerbations by autoantibodies in patients with idiopathic interstitial pneumonia.

Shusuke Yazawa, Noriyuki Enomoto, Shogo Nakai, Yasutaka Mochizuka, Atsuki Fukada, Yuko Tanaka, Hyogo Naoi, Yusuke Inoue, Hideki Yasui, Masato Karayama and 24 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Shusuke YazawaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Noriyuki EnomotoSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. norieno@hama-med.ac.jp.
Shogo NakaiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yasutaka MochizukaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Atsuki FukadaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yuko TanakaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hyogo NaoiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yusuke InoueSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hideki YasuiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Masato KarayamaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Yuzo SuzukiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hironao HozumiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kazuki FuruhashiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Mikio ToyoshimaDepartment of Respiratory Medicine, Hamamatsu Rosai Hospital, Hamamatsu, Japan.
Masato KonoDepartment of Respiratory Medicine, Seirei Hamamatsu General Hospital, Hamamatsu, Japan.
Shiro ImokawaDepartment of Respiratory Medicine, Iwata City Hospital, Iwata, Japan.
Masato FujiiDepartment of Respiratory Medicine, Shizuoka City Shizuoka Hospital, Shizuoka, Japan.
Taisuke AkamatsuDepartment of Respiratory Medicine, Shizuoka General Hospital, Shizuoka, Japan.
Naoki KoshimizuDepartment of Respiratory Medicine, Fujieda Municipal General Hospital, Fujieda, Japan.
Koshi YokomuraDepartment of Respiratory Medicine, Respiratory Disease Center, Seirei Mikatahara General Hospital, Hamamatsu, Japan.
Hiroyuki MatsudaDepartment of Respiratory Medicine, Japanese Red Cross Shizuoka Hospital, Shizuoka, Japan.
Yusuke KaidaDepartment of Respiratory Medicine, Enshu Hospital, Hamamatsu, Japan.
Yutaro NakamuraRespiratory and Allergy Medicine, NHO Tenryu Hospital, Hamamatsu, Japan.
Masahiro ShiraiRespiratory and Allergy Medicine, NHO Tenryu Hospital, Hamamatsu, Japan.
Kazutaka MoriRespiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan.
Masafumi MasudaRespiratory Medicine, Shizuoka City Shimizu Hospital, Shizuoka, Japan.
Tomoyuki FujisawaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Naoki InuiSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Hiroaki SugiuraDepartment of Radiology, National Defense Medical College, Saitama, Japan.
Hiromitsu SumikawaDepartment of Radiology, National Hospital Organization Kinki-Chuo Chest Medical Center, Osaka, Japan.
Masashi KitaniDepartment of Pathology, NHO Tokyo National Hospital, Tokyo, Japan.
Kazuhiro TabataDepartment of Pathology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.
Noriyoshi OgawaDivision of Immunology and Rheumatology, Department of Internal Medicine 3, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Takafumi SudaSecond Division, Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although acute exacerbation of idiopathic interstitial pneumonia (AE-IIP) is a critical event, the detailed features of connective tissue diseases (CTD) that affect the incidence of AE-IIP have not been fully elucidated. This study aimed to clarify the CTD-related features that affect the incidence of AE-IIP. This was a post hoc analysis of a prospective and multicenter cohort study conducted between 2015 and 2020. Newly diagnosed patients with IIP were consecutively enrolled, and 74 autoimmune features and autoantibodies were comprehensively checked during IIP diagnosis. In total, 222 patients with IIP were enrolled. The median observation period was 36 months, during which 34 patients developed AE-IIP. In multivariate models adjusted for age, gender, and %predicted FVC, AE-IIP frequently occurred in patients positive for anti-cyclic citrullinated peptide (CCP) antibody (hazard ratio [HR]: 4.407, p = 0.004, q = 0.027), while it was less common in patients positive for antinuclear antibodies (ANA) ≥ 320 or polymyositis/dermatomyositis (PM/DM)- or systemic sclerosis (SSc)-related antibodies (HR < 0.001, p < 0.001, q < 0.001). A composite model consisting of these items stratified the incidence of AE-IIP (p < 0.001), which was closely related to the mortality. These results indicate that the presence of anti-CCP antibodies, ANA, or PM/DM/SSc-related antibodies, in addition to decreased lung function, could help determine the risk of AE-IIP in patients with IIP.

Indexed as

AutoantibodiesIdiopathic Interstitial PneumoniasAdultAgedAntibodies, AntinuclearAnti-Citrullinated Protein AntibodiesDisease ProgressionFemaleHumansIncidenceMaleMiddle AgedProspective StudiesRisk AssessmentRisk FactorsAntibodies, AntinuclearAnti-Citrullinated Protein AntibodiesAutoantibodiesAcute exacerbationConnective tissue diseaseIdiopathic interstitial pneumoniaInterstitial pneumonia with autoimmune features

Identifiers

PMID41083568
PMCPMC12518612

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.